Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssptajsl1623

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	JAN 02	STN pricing information for 2008 now available
NEWS 3	JAN 16	CAS patent coverage enhanced to include exemplified prophetic substances
NEWS 4	JAN 28	USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats
NEWS 5	JAN 28	MARPAT searching enhanced
NEWS 6	JAN 28	USGENE now provides USPTO sequence data within 3 days of publication
NEWS 7	JAN 28	TOXCENTER enhanced with reloaded MEDLINE segment
NEWS 8	JAN 28	MEDLINE and LMEDLINE reloaded with enhancements
NEWS 9	FEB 08	STN Express, Version 8.3, now available
NEWS 10	FEB 20	PCI now available as a replacement to DPCI
NEWS 11	FEB 25	IFIREF reloaded with enhancements
NEWS 12	FEB 25	IMSPRODUCT reloaded with enhancements
NEWS 13	FEB 29	WPINDEX/WPIDS/WPIX enhanced with ECLA and current U.S. National Patent Classification
NEWS 14	MAR 31	IFICDB, IFIPAT, and IFIUDB enhanced with new custom IPC display formats
NEWS 15	MAR 31	CAS REGISTRY enhanced with additional experimental spectra
NEWS 16	MAR 31	CA/CAplus and CASREACT patent number format for U.S. applications updated
NEWS 17	MAR 31	LPCI now available as a replacement to LDPCI
NEWS 18	MAR 31	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS 19	APR 04	STN AnaVist, Version 1, to be discontinued
NEWS 20	APR 15	WPIDS, WPINDEX, and WPIX enhanced with new predefined hit display formats

NEWS EXPRESS FEBRUARY 08 CURRENT WINDOWS VERSION IS V8.3,
AND CURRENT DISCOVER FILE IS DATED 20 FEBRUARY 2008

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items
NEWS IPC8	For general information regarding STN implementation of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 08:28:58 ON 15 APR 2008

=> b reg
COST IN U.S. DOLLARS   SINCE FILE   TOTAL
                                                         ENTRY   SESSION
FULL ESTIMATED COST   0.21   0.21

FILE 'REGISTRY' ENTERED AT 08:29:24 ON 15 APR 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 14 APR 2008 HIGHEST RN 1014671-54-5
DICTIONARY FILE UPDATES: 14 APR 2008 HIGHEST RN 1014671-54-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Documents and Settings\jlau1\My Documents\10550864 - bioreduction
prodrug\generic species.str





chain nodes :
10 11 12 13 14 16
ring nodes :
1 2 3 4 5 6 7 8 9
chain bonds :
9-10 10-11 11-12 11-13 11-16 14-16
ring bonds :
1-2 1-5 2-3 3-4 4-5 4-6 5-9 6-7 7-8 8-9
exact/norm bonds :
1-2 1-5 2-3 3-4 9-10 10-11 11-16 14-16
exact bonds :
11-12 11-13
normalized bonds :
4-5 4-6 5-9 6-7 7-8 8-9

G1:O,S,N

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 12:CLASS 13:CLASS 14:CLASS 16:Atom
Generic attributes :
16:
Saturation   : Unsaturated
Type of Ring System   : Monocyclic

L1 STRUCTURE UPLOADED

=> d l1
L1 HAS NO ANSWERS
L1 STR



G1 O,S,N

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam
SAMPLE SEARCH INITIATED 08:29:45 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 69 TO ITERATE

100.0% PROCESSED 69 ITERATIONS 0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 882 TO 1878
PROJECTED ANSWERS: 0 TO 0

L2 0 SEA SSS SAM L1

=> s l1 sss full
FULL SEARCH INITIATED 08:29:51 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 1478 TO ITERATE

100.0% PROCESSED 1478 ITERATIONS 3 ANSWERS
SEARCH TIME: 00.00.01

L3 3 SEA SSS FUL L1

=> d l3 1-3

L3 ANSWER 1 OF 3 REGISTRY COPYRIGHT 2008 ACS on STN
RN 948856-26-6 REGISTRY

ED Entered STN: 30 Sep 2007
CN 9H-Purin-2-amine, 6-[[1-methyl-1-(4-nitrophenyl)ethyl]thio]- (CA INDEX NAME)
MF C14 H14 N6 O2 S
SR CA
LC STN Files: CA, CAPLUS, CASREACT, TOXCENTER



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L3 ANSWER 2 OF 3 REGISTRY COPYRIGHT 2008 ACS on STN
RN 770746-94-6 REGISTRY
ED Entered STN: 28 Oct 2004
CN 1H-Purine, 6-[[1-methyl-1-(5-nitro-2-thienyl)ethyl]thio]- (9CI) (CA INDEX NAME)
OTHER NAMES:
CN 6-[2-(5-Nitrothien-2-yl)propan-2-ylsulfanyl]-9H-purine
MF C12 H11 N5 O2 S2
SR CA
LC STN Files: CA, CAPLUS, CASREACT, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

L3 ANSWER 3 OF 3 REGISTRY COPYRIGHT 2008 ACS on STN
RN 770746-91-3 REGISTRY
ED Entered STN: 28 Oct 2004
CN 9H-Purine, 6-[[1-methyl-1-(4-nitrophenyl)ethyl]thio]- (CA INDEX NAME)
OTHER CA INDEX NAMES:
CN 1H-Purine, 6-[[1-methyl-1-(4-nitrophenyl)ethyl]thio]- (9CI)
OTHER NAMES:
CN 6-[2-(4-Nitrophenyl)propan-2-ylsulfanyl]-9H-purine
MF C14 H13 N5 O2 S
SR CA
LC STN Files: CA, CAPLUS, CASREACT, TOXCENTER, USPATFULL



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

2 REFERENCES IN FILE CA (1907 TO DATE)
2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> b caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	184.82	185.03

FILE 'CAPLUS' ENTERED AT 08:30:22 ON 15 APR 2008

FILE COVERS 1907 - 15 Apr 2008 VOL 148 ISS 16
FILE LAST UPDATED: 14 Apr 2008 (20080414/ED)

=> s l3
L4   2 L3

=> d l4 scan

L4   2 ANSWERS   CAPLUS COPYRIGHT 2008 ACS on STN
IC   ICM C07D333-36
     ICS C07D417-04; C07D233-54; A61K031-445
CC   27-8 (Heterocyclic Compounds (One Hetero Atom))
     Section cross-reference(s): 1, 28, 33, 63
TI   Preparation of bioreductively activated prodrugs of antiproliferative
     agents
ST   thiophene propoxy prodrug prepn bioreductive activation antiproliferative
     agent
IT   Antibiotics
        (anthracycline; release of cytostatic agents under hypoxic conditions
        from bioreductively activated prodrugs)
IT   Cytotoxic agents
        (antimetabolites, cytostatic agent; release of cytostatic agents under
        hypoxic conditions from bioreductively activated prodrugs)
IT   Eye, disease
        (diabetic retinopathy; preparation of bioreductively activated prodrugs of
        antiproliferative agents)
IT   Macrolides
     RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
     (Biological study); USES (Uses)
        (epothilones; release of cytostatic agents under hypoxic conditions
        from bioreductively activated prodrugs)
IT   Mitosis
        (inhibitor; release of cytostatic agents under hypoxic conditions from
        bioreductively activated prodrugs)
IT   Eye, disease
        (macula, senile degeneration, treatment of wet; preparation of
        bioreductively activated prodrugs of antiproliferative agents)
IT   Antirheumatic agents
     Antitumor agents
     Cytotoxic agents
     Human
     Hypoxia
     Leukemia
     Neoplasm
     Psoriasis
     Rheumatoid arthritis
        (preparation of bioreductively activated prodrugs of antiproliferative
        agents)
IT   Drug delivery systems
        (prodrugs; preparation of bioreductively activated prodrugs of
        antiproliferative agents)
IT   Disease, animal

(proliferative; preparation of bioreductively activated prodrugs of antiproliferative agents)

IT Neoplasm
(solid; preparation of bioreductively activated prodrugs of antiproliferative agents)

IT 62989-33-7, (6R)-5,6,7,8-Tetrahydrobiopterin
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(antagonist of; release of cytostatic agents under hypoxic conditions from bioreductively activated prodrugs)

IT 770746-88-8P, 1-[4-Methoxy-3-[[2-(5-nitrothiophen-2-yl)propan-2-yl]oxy]phenyl]-2-(3,4,5-trimethoxyphenyl)-(Z)-ethene 770746-89-9P, 1-[4-Methoxy-3-[[2-(4-nitrophenyl)propan-2-yl]oxy]phenyl]-2-(3,4,5-trimethoxyphenyl)-(Z)-ethene 770746-90-2P 770746-91-3P, 6-[2-(4-Nitrophenyl)propan-2-ylsulfanyl]-9H-purine 770746-92-4P, 1-[4-Methoxy-3-[[[[1-methyl-4-(5-nitrothien-2-yl)piperidin-4-yl]oxy]carbonyl]oxy]phenyl]-2-(3,4,5-trimethoxyphenyl)-(Z)-ethene 770746-93-5P, 1-[4-Methoxy-3-[[2-(1-methyl-2-nitroimidazol-5-yl)propan-2-yl]oxy]phenyl]-2-(3,4,5-trimethoxyphenyl)-(Z)-ethene 770746-94-6P, 6-[2-(5-Nitrothien-2-yl)propan-2-ylsulfanyl]-9H-purine 770746-95-7P 770746-96-8P, 1-[3-[1-Ethoxycarbonyl-1-(5-nitrothien-2-yl)ethoxy]-4-methoxyphenyl]-2-(3,4,5-trimethoxyphenyl)-(Z)-ethene 770746-97-9P, N-[2-[3-[1-Methyl-1-(5-nitrothiophen-2-yl)ethoxy]phenyl]ethyl]acetamide
RL: SPN (Synthetic preparation); PREP (Preparation)
(bioreductive prodrug; preparation of bioreductively activated prodrugs of antiproliferative agents)

IT 80449-01-0, Topoisomerase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitor; release of cytostatic agents under hypoxic conditions from bioreductively activated prodrugs)

IT 372092-80-3, Protein kinase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(inhibitors; release of cytostatic agents under hypoxic conditions from bioreductively activated prodrugs)

IT 770746-98-0P, 4-Hydroxy-1-methyl-4-(5-nitrothien-2-yl)piperidine 770747-00-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of bioreductively activated prodrugs of antiproliferative agents)

IT 9039-06-9, Cytochrome p450 reductase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(preparation of bioreductively activated prodrugs of antiproliferative agents)

IT 50-44-2, 6-Mercaptopurine 117048-59-6, Combretastatin A4
RL: PAC (Pharmacological activity); RCT (Reactant); THU (Therapeutic use); BIOL (Biological study); RACT (Reactant or reagent); USES (Uses)
(preparation of bioreductively activated prodrugs of antiproliferative agents)

IT 147-94-4, Cytarabine
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(preparation of bioreductively activated prodrugs of antiproliferative agents)

IT 609-40-5, 2-Nitrothiophene 1445-73-4, 1-Methylpiperidin-4-one 6742-07-0 41765-97-3, N-Acetyl-3-(2-aminoethyl)phenol 60628-92-4, 5-(1-Hydroxy-1-methylethyl)-1-methyl-2-nitro-1H-imidazole 69240-39-7, 1-Methyl-1-(5-nitrothiophen-2-yl)ethanol 70951-50-7, 2-Bromo-2-(4-nitrophenyl)propane 226972-65-2, Ethyl 2-hydroxy-2-(5-nitrothien-2-yl)propanoate 770746-99-1, 2-Chloro-2-(5-nitrothien-2-

yl)propane
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of bioreductively activated prodrugs of antiproliferative agents)

IT 51-21-8, 5-Fluorouracil 57-22-7, Vincristine 59-05-2, Methotrexate 154-42-7, 6-Thioguanine 320-67-2, 5-Azacytidine 518-28-5, Podophyllotoxin 865-21-4, Vinblastine 2353-33-5, Decitabine 4291-63-8, Cladribine 20830-81-3, Daunorubicin 21679-14-1, Fludarabine 23214-92-8, Doxorubicin 26599-17-7, 4'-Thioaracytidine 29767-20-2, Teniposide 33069-62-4, Paclitaxel 33419-42-0, Etoposide 52128-35-5, Trimetrexate 56420-45-2, Epirubicin 71486-22-1, Vinorelbine 86639-52-3, SN 38 95058-81-4, Gemcitabine 109971-63-3, Combretastatin A1 114977-28-5, Docetaxel 123318-82-1, Clofarabine 123948-87-8, Topotecan 130306-02-4, Tezacitabine 145918-75-8, Troxacitabine 154361-50-9, Capecitabine 183321-74-6, Erlotinib 184475-35-2, Gefitinib 443913-73-3, ZD6474
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(release of cytostatic agents under hypoxic conditions from bioreductively activated prodrugs)

IT 9037-80-3, Reductase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(use bioreductively activated stilbene prodrugs with a reductase, an antibody-reductase conjugate, a macromol.-reductase conjugate or DNA encoding a reductase gene for treating proliferative disorders)

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L4 2 ANSWERS CAPLUS

CC 63-6 (Pharmaceuticals)
Section cross-reference(s): 1, 26

TI Hypoxia-driven elimination of thiopurines from their nitrobenzyl prodrugs

ST nitrobenzyl thioguanine mercaptopurine prepn antitumor prodrug; radical half life nitrobenzyl thioguanine mercaptopurine gamma pulse radiolysis; rate release thioguanine mercaptopurine gamma pulse radiolysis; hypoxia selective release thioguanine nitrobenzyl prodrug A549 cell; antitumor prodrug nitrobenzyl thioguanine mercaptopurine selective release hypoxia; elimination driven hypoxia thiopurine nitrobenzyl prodrug; structure nitrobenzyl thioguanine mercaptopurine release antitumor agent hypoxia

IT Human
Lung, neoplasm
(preparation of S-nitrobenzyl thioguanines and an S-benzylmercaptopurine as hypoxia-selective prodrugs for antitumor agents and release of thioguanine in A549 human lung cancer cells under aerobic and hypoxic conditions)

IT Antitumor agents
Fragmentation reaction
Hypoxia
Prodrugs
(preparation of S-nitrobenzyl thioguanines and an S-benzylmercaptopurine as hypoxia-selective prodrugs for antitumor agents, release of thiols upon γ-pulse irradiation and of thioguanine in A549 cells under aerobic and hypoxic conditions)

IT 50-44-2, 6-Mercaptopurine 154-42-7, 6-Thioguanine
RL: FMU (Formation, unclassified); RCT (Reactant); FORM (Formation, nonpreparative); RACT (Reactant or reagent)
(preparation of S-nitrobenzyl thioguanines and an S-benzylmercaptopurine as hypoxia-selective prodrugs for antitumor agents, release of thiols upon γ-pulse irradiation and of thioguanine in A549 cells under aerobic

and hypoxic conditions)

IT 5069-64-7P *770746-91-3P* *948856-26-6P*
RL: PAC (Pharmacological activity); PEP (Physical, engineering or chemical process); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation); PROC (Process)
(preparation of S-nitrobenzyl thioguanines and an S-benzylmercaptopurine as hypoxia-selective prodrugs for antitumor agents, release of thiols upon γ-pulse irradiation and of thioguanine in A549 cells under aerobic and hypoxic conditions)

IT 100-11-8, 4-Nitrobenzyl bromide 70951-50-7
RL: RCT (Reactant); RACT (Reactant or reagent)
(preparation of S-nitrobenzyl thioguanines and an S-benzylmercaptopurine as hypoxia-selective prodrugs for antitumor agents, release of thiols upon γ-pulse irradiation and of thioguanine in A549 cells under aerobic and hypoxic conditions)

ALL ANSWERS HAVE BEEN SCANNED

=> d l4 1-2 ibib

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2007:746502 CAPLUS
DOCUMENT NUMBER: 147:350314
TITLE: Hypoxia-driven elimination of thiopurines from their nitrobenzyl prodrugs
AUTHOR(S): Thomson, Peter; Naylor, Matthew A.; Stratford, Michael R. L.; Lewis, Gemma; Hill, Sally; Patel, Kantilal B.; Wardman, Peter; Davis, Peter D.
CORPORATE SOURCE: University of Oxford, Gray Cancer Institute, Mount Vernon Hospital, Middlesex, HA6 2JR, UK
SOURCE: Bioorganic & Medicinal Chemistry Letters (2007), 17(15), 4320-4322
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 147:350314
REFERENCE COUNT: 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:817879 CAPLUS
DOCUMENT NUMBER: 141:332039
TITLE: Preparation of bioreductively activated prodrugs of antiproliferative agents
INVENTOR(S): Davis, Peter David; Naylor, Matthew Alexander; Thomson, Peter; Everett, Steven Albert; Stratford, Michael Richard Lacey; Wardman, Peter
PATENT ASSIGNEE(S): Angiogene Pharmaceuticals Limited, UK; Gray Laboratory Cancer Research Trust
SOURCE: PCT Int. Appl., 45 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

```
     ---------------     ----   --------    --------------------   --------
     WO 2004085421        A2    20041007    WO 2004-GB1330          20040326
     WO 2004085421        A3    20050324
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
             NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
             TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ,
             BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE,
             ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI,
             SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN,
             TD, TG
     AU 2004224070        A1    20041007    AU 2004-224070          20040326
     CA 2519901           A1    20041007    CA 2004-2519901         20040326
     EP 1613612           A2    20060111    EP 2004-723650          20040326
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK
     CN 1791591           A     20060621    CN 2004-80013946        20040326
     JP 2006523202        T     20061012    JP 2006-506035          20040326
     IN 2005CN02380       A     20070803    IN 2005-CN2380          20050923
     US 20070099871       A1    20070503    US 2005-550864          20051027
PRIORITY APPLN. INFO.:                      GB 2003-6907         A  20030326
                                            WO 2004-GB1330       W  20040326
OTHER SOURCE(S):         CASREACT 141:332039; MARPAT 141:332039


=> logoff hold
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       3.86     188.89

 SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 08:32:10 ON 15 APR 2008

Connecting via Winsock to STN



Welcome to STN International!  Enter x:x

LOGINID:ssptajsl1623

PASSWORD:
 * * * * * * RECONNECTED TO STN INTERNATIONAL * * * * * *
SESSION RESUMED IN FILE 'CAPLUS' AT 09:51:49 ON 15 APR 2008
FILE 'CAPLUS' ENTERED AT 09:51:49 ON 15 APR 2008
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       3.86     188.89

=> b marpat
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                       3.86     188.89
```

```
FILE 'MARPAT' ENTERED AT 09:52:04 ON 15 APR 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

FILE CONTENT: 1961-PRESENT VOL 148 ISS 14 (20080411/ED)

SOME MARPAT RECORDS ARE DERIVED FROM INPI DATA FOR 1961-1987

MOST RECENT CITATIONS FOR PATENTS FROM MAJOR ISSUING AGENCIES
(COVERAGE TO THESE DATES IS NOT COMPLETE):

US  20080051413 28 FEB 2008
DE 102006039038 21 FEB 2008
EP      1889831 20 FEB 2008
JP   2008044933 28 FEB 2008
WO   2008028336 13 MAR 2008
GB      2440819 13 FEB 2008
FR      2904973 22 FEB 2008
RU      2317993 27 FEB 2008
CA      2593150 06 JAN 2008

Expanded G-group definition display now available.

Effective December 15th the iteration and answer limits in MARPAT
have increased from 100,000 to 200,000 for both on-line and batch
searches.  For more information on MARPAT search limits, type HELP
SLIMITS at an arrow prompt.

=> d his

     (FILE 'HOME' ENTERED AT 08:28:58 ON 15 APR 2008)

     FILE 'REGISTRY' ENTERED AT 08:29:24 ON 15 APR 2008
L1              STRUCTURE UPLOADED
L2            0 S L1 SSS SAM
L3            3 S L1 SSS FULL

     FILE 'CAPLUS' ENTERED AT 08:30:22 ON 15 APR 2008
L4            2 S L3

     FILE 'MARPAT' ENTERED AT 09:52:04 ON 15 APR 2008

=> s l3 sss sam
SAMPLE SEARCH INITIATED 09:52:13 FILE 'MARPAT'
SAMPLE SCREEN SEARCH COMPLETED -      187 TO ITERATE

100.0% PROCESSED      187 ITERATIONS                                0 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:          2923 TO     4557
PROJECTED ANSWERS:                0 TO        0

L5            0 SEA SSS SAM L1

=> s l3 sss full
```

```
FULL SEARCH INITIATED 09:52:19 FILE 'MARPAT'
FULL SCREEN SEARCH COMPLETED -     3552 TO ITERATE

 98.3% PROCESSED     3491 ITERATIONS                              21 ANSWERS

 98.3% PROCESSED     3491 ITERATIONS                              21 ANSWERS

100.0% PROCESSED     3552 ITERATIONS  (     1 INCOMPLETE)       22 ANSWERS
SEARCH TIME: 00.00.34

L6           22 SEA SSS FUL L1

=> s l6 and py<=2003
'2003' NOT A VALID FIELD CODE
             0 PY<=2003
L7           0 L6 AND PY<=2003

=> d l6 scan

L6   22 ANSWERS   MARPAT  COPYRIGHT 2008 ACS on STN
NCL  424725000
CC   1-11 (Pharmacology)
     Section cross-reference(s): 28, 63
TI   Therapeutic Gastrodia extracts
ST   Huntington's disease Gastrodia ext bishydroxybenzylsulfide
IT   Nervous system, disease
        (Huntington's chorea; therapeutic Gastrodia exts.)
IT   Drug delivery systems
     Gastrodia
     Gastrodia elata
     Natural products, pharmaceutical
        (therapeutic Gastrodia exts.)
IT   38204-93-2P
     RL: PAC (Pharmacological activity); PUR (Purification or recovery); SPN
     (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study);
     PREP (Preparation); USES (Uses)
        (therapeutic Gastrodia exts.)
IT   110505-75-4P
     RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic
     preparation); THU (Therapeutic use); BIOL (Biological study); PREP
     (Preparation); RACT (Reactant or reagent); USES (Uses)
        (therapeutic Gastrodia exts.)
IT   58-61-7, Adenosine, reactions   100-07-2, 4-Methoxybenzoyl chloride
     6258-60-2, (4-Methoxyphenyl)methanethiol
     RL: RCT (Reactant); RACT (Reactant or reagent)
        (therapeutic Gastrodia exts.)
IT   23666-24-2P   54373-32-9P   56883-05-7P
     RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
     (Reactant or reagent)
        (therapeutic Gastrodia exts.)
```

MSTR *1A*



G1 = phenylene (opt. substd.)

G2 = 115-5 110-7



G4 = carbon chain <containing 1 or more C>
(opt. substd.)
G5 = bond
G6 = O
G10 = NO2
Patent location: disclosure
Note: and pharmaceutically acceptable salts and solvates
Note: substitution is restricted

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L6 22 ANSWERS MARPAT COPYRIGHT 2008 ACS on STN
CC 26-9 (Biomolecules and Their Synthetic Analogs)
Section cross-reference(s): 1, 28, 63
TI Preparation of sulfonamido purine aniline derivatives as Janus kinase inhibitors
ST sulfonamido purine aniline prepn JAK2 kinase inhibitor; proliferative disease treatment sulfonamido purine aniline prepn
IT Antitumor agents
Cytotoxic agents
Human
Neoplasm
(preparation of sulfonamido purine aniline derivs. as JAK2 kinase inhibitors for the treatment of proliferative disease)
IT Sulfonamides
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of sulfonamido purine aniline derivs. as JAK2 kinase inhibitors for the treatment of proliferative disease)
IT Disease, animal
(proliferative; preparation of sulfonamido purine aniline derivs. as JAK2 kinase inhibitors for the treatment of proliferative disease)
IT Pharmaceutical capsules
(soft capsules; preparation of sulfonamido purine aniline derivs. as JAK2 kinase inhibitors for the treatment of proliferative disease)
IT 152478-57-4, JAK2 kinase
RL: BSU (Biological study, unclassified); BIOL (Biological study)
(preparation of sulfonamido purine aniline derivs. as JAK2 kinase inhibitors for the treatment of proliferative disease)
IT 934595-55-8P 942475-75-4P 942475-76-5P 942475-77-6P 942475-78-7P
942475-79-8P 942475-80-1P 942475-81-2P 942475-82-3P 942475-83-4P
942475-84-5P 942475-85-6P 942475-86-7P 942475-87-8P 942475-88-9P
942475-89-0P 942475-90-3P 942475-91-4P 942475-92-5P 942475-93-6P
942475-94-7P 942475-95-8P 942475-96-9P 942475-97-0P 942475-98-1P
942475-99-2P 942476-00-8P 942476-01-9P 942476-02-0P 942476-03-1P
942476-04-2P 942476-05-3P 942476-06-4P 942476-07-5P 942476-08-6P
942476-09-7P 942476-10-0P 942476-11-1P 942476-12-2P 942476-13-3P

942476-14-4P 942476-15-5P 942476-16-6P 942476-17-7P 942476-18-8P
942476-19-9P 942476-20-2P 942476-21-3P 942476-22-4P 942476-23-5P
942476-24-6P 942476-25-7P 942476-26-8P 942476-27-9P 942476-28-0P
942476-29-1P 942476-30-4P 942476-31-5P 942476-32-6P 942476-33-7P
942476-34-8P 942476-35-9P 942476-36-0P 942476-37-1P 942476-38-2P
942476-39-3P 942476-40-6P 942476-41-7P 942476-42-8P 942476-43-9P
942476-44-0P 942476-45-1P 942476-46-2P 942476-47-3P 942476-48-4P
942476-49-5P 942476-50-8P 942476-51-9P 942476-52-0P 942476-53-1P
942476-54-2P 942476-55-3P 942476-56-4P 942476-57-5P 942476-58-6P
942476-59-7P 942476-60-0P 942476-61-1P 942476-62-2P 942476-63-3P
942476-64-4P 942476-65-5P 942476-66-6P 942476-67-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of sulfonamido purine aniline derivs. as JAK2 kinase inhibitors for the treatment of proliferative disease)

IT 51-45-6, 2-(1H-Imidazol-4-yl)ethylamine, reactions 75-31-0, Isopropylamine, reactions 96-41-3, Cyclopentanol 99-09-2, 3-Nitroaniline 100-46-9, Benzylamine, reactions 100-49-2, Cyclohexylmethanol 100-51-6, Benzyl alcohol, reactions 108-00-9, 2-Dimethylaminoethylamine 109-01-3, N-Methylpiperazine 109-56-8, 2-Isopropylaminoethanol 109-86-4, 2-Methoxyethanol 110-91-8, Morpholine, reactions 121-05-1, 2-Diisopropylaminoethylamine 123-75-1, Pyrrolidine, reactions 124-68-5, 2-Amino-2-methyl-1-propanol 180-76-7, 1,4-Diazaspiro[5.5]undecane 280-57-9, 1,4-Diazabicyclo[2.2.2]octane 371-41-5, 4-Fluorophenol 453-20-3, 3-Hydroxytetrahydrofuran 616-30-8, 3-Amino-1,2 propanediol 693-05-0, 3-Methylaminopropionitrile 765-30-0, Cyclopropylamine 822-36-6, 4-Methylimidazole 932-30-9, 2-Aminomethylphenol 1003-03-8, Cyclopentylamine 1008-91-9, 1-(4-Pyridyl)piperazine 2026-48-4, (S)-2-Amino-3-methylbutan-1-ol 2038-03-1, 4-(2-Aminoethyl)morpholine 2516-34-9, Cyclobutylamine 2627-86-3, (S)-1-Phenylethylamine 2706-56-1, 2-(2-Aminoethyl)pyridine 2740-83-2, 3-Trifluoromethylbenzylamine 3014-80-0 3731-52-0, 3-Pyridylmethylamine 3789-59-1, (S)-1-Phenylpropylamine 3886-69-9, (R)-1-Phenylethylamine 4152-92-5 4276-09-9, (R)-2-Amino-3-methylbutan-1-ol 4403-70-7, 3-Aminomethylphenylamine 4747-21-1, Isopropylmethylamine 5071-96-5, 3-Methoxybenzylamine 5813-64-9, Neopentylamine 6530-09-2, 3-Aminoquinuclidine dihydrochloride 7409-18-9, 3-Nitrobenzylamine 10406-24-3, 3-Aminomethylbenzonitrile 19293-58-4, 4-Dimethylaminobenzylamine 19522-67-9, N-Isopropylethane-1,2-diamine 20419-68-5, 2,6-Dichloro-9-(tetrahydropyran-2-yl)-9H-purine 22526-47-2, (S)-1,2,2-Trimethylpropylamine 22990-77-8, 2-(Aminomethyl)piperidine 23356-96-9, S-2-(Hydroxymethyl)pyrrolidine 31519-52-5 31519-53-6 37045-73-1, N-(3-Aminophenyl)methanesulfonamide 40499-83-0, 3-Pyrrolidinol 53557-47-4 57678-46-3, 3-Dimethylaminobenzylamine 66228-31-7, (R)-1,2,2-Trimethylpropylamine 68327-04-8 73604-31-6, 3-Aminomethylphenol 86087-23-2, (S)-(+)-3-Hydroxytetrahydrofuran 86087-24-3, (R)-(-)-3-Hydroxytetrahydrofuran 87781-93-9 93071-75-1, 3-Trifluoromethoxybenzylamine 96783-68-5, N-(3-Aminomethylphenyl)acetamide 112245-09-7, (R)-2-Amino-3,3-dimethylbutan-1-ol 112245-13-3, (S)-2-Amino-3,3-dimethylbutan-1-ol 125593-25-1 137254-03-6, (1R,2S)-2-Aminocyclopentanol hydrochloride 138799-95-8 149917-33-9 158849-15-1 162679-02-9 167321-08-6 167321-10-0 321330-19-2, 2,1,3-Benzoxadiazole-5-methanamine 672325-37-0 749789-43-3 771573-22-9 849020-90-2, N-(3-Aminomethylphenyl)-N-methylacetamide hydrochloride 881407-20-1 886766-44-5 942476-78-0 942476-79-1 942476-80-4 942476-81-5 942579-86-4
RL: RCT (Reactant); RACT (Reactant or reagent)

(preparation of sulfonamido purine aniline derivs. as JAK2 kinase inhibitors for the treatment of proliferative disease)

IT 23384-29-4P 942476-68-8P 942476-69-9P 942476-70-2P 942476-71-3P 942476-72-4P 942476-73-5P 942476-74-6P 942476-75-7P 942476-76-8P 942476-77-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of sulfonamido purine aniline derivs. as JAK2 kinase inhibitors for the treatment of proliferative disease)

MSTR 1



G6 = N
G7 = 61



G9 = alkyl (opt. substd. by G11)
G10 = O
G11 = Ph (opt. substd. by G12)
G12 =
Patent location: claim 1
Note: additional substitution also claimed
Note: or salts

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):end

=> d his

(FILE 'HOME' ENTERED AT 08:28:58 ON 15 APR 2008)

FILE 'REGISTRY' ENTERED AT 08:29:24 ON 15 APR 2008
L1 STRUCTURE UPLOADED
L2 0 S L1 SSS SAM
L3 3 S L1 SSS FULL

FILE 'CAPLUS' ENTERED AT 08:30:22 ON 15 APR 2008
L4 2 S L3

FILE 'MARPAT' ENTERED AT 09:52:04 ON 15 APR 2008
L5 0 S L3 SSS SAM
L6 22 S L3 SSS FULL
L7 0 S L6 AND PY<=2003

=> b caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION

FULL ESTIMATED COST 66.34 255.23

FILE 'CAPLUS' ENTERED AT 09:54:27 ON 15 APR 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 15 Apr 2008 VOL 148 ISS 16
FILE LAST UPDATED: 14 Apr 2008 (20080414/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l6
L8 22 L6

=> s l8 and py<=2003
23980312 PY<=2003
L9 8 L8 AND PY<=2003

=> d l9 1-8 ibib

L9 ANSWER 1 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:814853 CAPLUS
DOCUMENT NUMBER: *137:325431*
TITLE: Preparation of aminopyrimidines and -pyridines as glycogen synthase kinase 3 inhibitors
INVENTOR(S): Nuss, John M.; Harrison, Stephen D.; Ring, David B.; Boyce, Rustum S.; Johnson, Kirk; Pfister, Keith B.; Ramurthy, Savithri; Seely, Lynn; Wagman, Allan S.; Desai, Manjo; Levine, Barry H.
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 134 pp., Cont.-in-part of U.S. 6,417,185.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20020156087	A1	20021024	US 2001-949035	20010906 <--
US 7045519	B2	20060516		
US 6417185	B1	20020709	US 1999-336038	19990618 <--
US 20030130289	A1	20030710	US 2002-309535	20021203 <--

US 7037918	B2	20060502			
US 20060089369	A1	20060427	US 2005-220400		20050906
PRIORITY APPLN. INFO.:			US 1998-89978P	P	19980619
			US 1999-336038	A2	19990618
			US 2000-230480P	P	20000906
			US 1999-336098	A3	19990618
			US 2001-949035	A3	20010906

OTHER SOURCE(S): MARPAT 137:325431
REFERENCE COUNT: 306 THERE ARE 306 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:185092 CAPLUS
DOCUMENT NUMBER: *136:247598*
TITLE: Preparation of aminopyrimidines and -pyridines as glycogen synthase kinase 3 inhibitors
INVENTOR(S): Nuss, John M.; Harrison, Stephen D.; Ring, David B.; Boyce, Rustum S.; Johnson, Kirk; Pfister, Keith B.; Ramurthy, Savithri; Seely, Lynn; Wagman, Allan S.; Desai, Manoj; Levine, Barry H.
PATENT ASSIGNEE(S): Chiron Corporation, USA
SOURCE: PCT Int. Appl., 268 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002020495	A2	20020314	WO 2001-US42081	20010906 <--
WO 2002020495	A3	20020620		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2001095026	A	20020322	AU 2001-95026	20010906 <--
EP 1317433	A2	20030611	EP 2001-975734	20010906 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004514656	T	20040520	JP 2002-525117	20010906
CN 1592743	A	20050309	CN 2001-818425	20010906
IN 2003KN00277	A	20050311	IN 2003-KN277	20030305
KR 816769	B1	20080326	KR 2003-703327	20030306
KR 2008013026	A	20080212	KR 2008-701887	20080124
PRIORITY APPLN. INFO.:			US 2000-230480P	P 20000906
			WO 2001-US42081	W 20010906
			KR 2003-703327	A3 20030306

OTHER SOURCE(S): MARPAT 136:247598

L9 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2001:763522 CAPLUS
DOCUMENT NUMBER: *135:283233*

TITLE: Pharmaceutical use of adenosine agonists for inducing bone marrow cell proliferation
INVENTOR(S): Fishman, Pnina; Cohn, Ilan
PATENT ASSIGNEE(S): Can-Fite Biopharma Ltd., Israel
SOURCE: U.S. Pat. Appl. Publ., 10 pp., Cont.-in-part of U.S. Ser. No. 700,744.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20010031742	A1	20011018	US 2001-782259	20010214 <--
US 6790839	B2	20040914		
WO 2000040251	A1	20000713	WO 2000-IL14	20000107 <--
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6638914	B1	20031028	US 2001-700744	20010109 <--
US 20020037871	A1	20020328	US 2001-871963	20010604 <--

PRIORITY APPLN. INFO.:		
IL 1999-127947	A	19990107
WO 2000-IL14	P	20000107
US 2001-700744	A2	20010109
US 2001-782259	A2	20010214

OTHER SOURCE(S): MARPAT 135:283233
REFERENCE COUNT: 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1996:734085 CAPLUS
DOCUMENT NUMBER: *126:19178*
TITLE: Nucleotide inotropic agents
INVENTOR(S): Liang, Bruce T.
PATENT ASSIGNEE(S): University of Pennsylvania, USA
SOURCE: PCT Int. Appl., 56 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9629345	A1	19960926	WO 1996-US3911	19960322 <--
W: CA, JP, US				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 5712258	A	19980127	US 1995-409350	19950323 <--
US 6255292	B1	20010703	US 1997-875050	19970923 <--
US 20030186929	A1	20031002	US 2003-396200	20030325 <--
US 7348315	B2	20080325		

PRIORITY APPLN. INFO.:		
US 1995-409350	A2	19950323
WO 1996-US3911	W	19960322

				US 1997-875050	A2 19970923
				US 2000-641491	B1 20000818

OTHER SOURCE(S): MARPAT 126:19178

L9 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1995:315533 CAPLUS
DOCUMENT NUMBER: *122:106398*
TITLE: Preparation of deoxythionucleosides as virucides
INVENTOR(S): Koszalka, George Walter; Van Draanen, Nanine Agneta; Freeman, George Andrew; Short, Steven Andersen
PATENT ASSIGNEE(S): Wellcome Foundation Ltd., UK
SOURCE: PCT Int. Appl., 56 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9401443	A1	19940120	WO 1993-GB1388	19930701 <--
W: AU, BB, BG, BR, CA, CZ, FI, HU, JP, KP, KR, KZ, LK, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, US, VN				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9345085	A	19940131	AU 1993-45085	19930701 <--
CN 1087089	A	19940525	CN 1993-109525	19930701 <--
ZA 9304742	A	19950103	ZA 1993-4742	19930701 <--
EP 648218	A1	19950419	EP 1993-914865	19930701 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 07508531	T	19950921	JP 1993-503083	19930701 <--

PRIORITY APPLN. INFO.:			GB 1992-14171	A	19920702
			GB 1992-23180	A	19921105
			WO 1993-GB1388	A	19930701

OTHER SOURCE(S): CASREACT 122:106398; MARPAT 122:106398

L9 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1991:247683 CAPLUS
DOCUMENT NUMBER: *114:247683*
TITLE: Preparation of N-heteroarylpurin-6-amines as analgesics and anticonvulsants
INVENTOR(S): Effland, Richard Charles; Klein, Joseph Thomas; Davis, Larry; Olson, Gordon Edward
PATENT ASSIGNEE(S): Hoechst-Roussel Pharmaceuticals, Inc., USA
SOURCE: Eur. Pat. Appl., 25 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 402752	A1	19901219	EP 1990-110676	19900606 <--
EP 402752	B1	19950913		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
US 5017578	A	19910521	US 1989-363837	19890609 <--
ES 2078267	T3	19951216	ES 1990-110676	19900606 <--
IL 94665	A	19940624	IL 1990-94665	19900607 <--

CA 2018563	A1	19901209	CA 1990-2018563		19900608 <--
CA 2018563	C	20000919			
NO 9002555	A	19901210	NO 1990-2555		19900608 <--
AU 9056919	A	19901213	AU 1990-56919		19900608 <--
AU 636351	B2	19930429			
CN 1047866	A	19901219	CN 1990-104194		19900608 <--
CN 1029968	B	19951011			
HU 54156	A2	19910128	HU 1990-3768		19900608 <--
HU 207320	B	19930329			
JP 03024080	A	19910201	JP 1990-148884		19900608 <--
JP 06102663	B	19941214			
ZA 9004443	A	19910327	ZA 1990-4443		19900608 <--
KR 199524	B1	19990615	KR 1990-8444		19900609 <--
US 5155098	A	19921013	US 1991-696472		19910506 <--
KR 210179	B1	19990715	KR 1998-49161		19981117 <--
PRIORITY APPLN. INFO.:			US 1989-363837	A	19890609
			KR 1990-8444	A	19900609

OTHER SOURCE(S): CASREACT 114:247683; MARPAT 114:247683

L9 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1991:143930 CAPLUS
DOCUMENT NUMBER: *114:143930*
TITLE: Preparation of 5'N, 6-disubstituted adenosines from inosines
INVENTOR(S): Bridges, Alexander J.
PATENT ASSIGNEE(S): Warner-Lambert Co., USA
SOURCE: U.S., 7 pp. Cont. of U.S. Ser. No. 34,125, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
US 4962194	A	19901009	US 1988-260202		19881019 <--
PRIORITY APPLN. INFO.:			US 1987-34125	B1	19870402

OTHER SOURCE(S): CASREACT 114:143930; MARPAT 114:143930

L9 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1990:423943 CAPLUS
DOCUMENT NUMBER: *113:23943*
TITLE: 6-Mercaptopurine derivatives, their preparation and their use against retrovirus infections
INVENTOR(S): Klosa, Josef; Kroeger, Hans Prof; Meichsner, Christoph; Winkler, Irvin; Helsberg, Matthias; Schrinner, Elmar
PATENT ASSIGNEE(S): Hoechst A.-G., Germany
SOURCE: Eur. Pat. Appl., 15 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 350742	A1	19900117	EP 1989-112061	19890701 <--
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				

```
     DE 3823345           A1    19900125    DE 1988-3823345        19880709 <--
     DK 8903383           A     19900110    DK 1989-3383           19890707 <--
     AU 8937933           A     19900111    AU 1989-37933          19890707 <--
     JP 02067283          A     19900307    JP 1989-174317         19890707 <--
     ZA 8905176           A     19900328    ZA 1989-5176           19890707 <--
PRIORITY APPLN. INFO.:                       DE 1988-3823345    A  19880709
OTHER SOURCE(S):         CASREACT 113:23943; MARPAT 113:23943


=> d his

     (FILE 'HOME' ENTERED AT 08:28:58 ON 15 APR 2008)

     FILE 'REGISTRY' ENTERED AT 08:29:24 ON 15 APR 2008
L1              STRUCTURE UPLOADED
L2            0 S L1 SSS SAM
L3            3 S L1 SSS FULL

     FILE 'CAPLUS' ENTERED AT 08:30:22 ON 15 APR 2008
L4            2 S L3

     FILE 'MARPAT' ENTERED AT 09:52:04 ON 15 APR 2008
L5            0 S L3 SSS SAM
L6           22 S L3 SSS FULL
L7            0 S L6 AND PY<=2003

     FILE 'CAPLUS' ENTERED AT 09:54:27 ON 15 APR 2008
L8           22 S L6
L9            8 S L8 AND PY<=2003

=> d l1
L1 HAS NO ANSWERS
L1              STR
```




```
G1 O,S,N


Structure attributes must be viewed using STN Express query preparation.


=> logoff hold
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
```

```
FULL ESTIMATED COST                                    12.28     267.51

 SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 09:54:59 ON 15 APR 2008

Connecting via Winsock to STN



Welcome to STN International!  Enter x:x

LOGINID:ssptajsl1623

PASSWORD:
 * * * * * * RECONNECTED TO STN INTERNATIONAL * * * * * *
SESSION RESUMED IN FILE 'CAPLUS' AT 10:02:30 ON 15 APR 2008
FILE 'CAPLUS' ENTERED AT 10:02:30 ON 15 APR 2008
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                      ENTRY    SESSION
FULL ESTIMATED COST                                   12.28     267.51

=> d his

     (FILE 'HOME' ENTERED AT 08:28:58 ON 15 APR 2008)

     FILE 'REGISTRY' ENTERED AT 08:29:24 ON 15 APR 2008
L1              STRUCTURE UPLOADED
L2            0 S L1 SSS SAM
L3            3 S L1 SSS FULL

     FILE 'CAPLUS' ENTERED AT 08:30:22 ON 15 APR 2008
L4            2 S L3

     FILE 'MARPAT' ENTERED AT 09:52:04 ON 15 APR 2008
L5            0 S L3 SSS SAM
L6           22 S L3 SSS FULL
L7            0 S L6 AND PY<=2003

     FILE 'CAPLUS' ENTERED AT 09:54:27 ON 15 APR 2008
L8           22 S L6
L9            8 S L8 AND PY<=2003

=> d l9 ibib abs hitstr

L9   ANSWER 1 OF 8  CAPLUS  COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER:        2002:814853  CAPLUS
DOCUMENT NUMBER:         137:325431
TITLE:                   Preparation of aminopyrimidines and -pyridines as
                         glycogen synthase kinase 3 inhibitors
INVENTOR(S):             Nuss, John M.; Harrison, Stephen D.; Ring, David B.;
                         Boyce, Rustum S.; Johnson, Kirk; Pfister, Keith B.;
                         Ramurthy, Savithri; Seely, Lynn; Wagman, Allan S.;
                         Desai, Manjo; Levine, Barry H.
PATENT ASSIGNEE(S):      USA
SOURCE:                  U.S. Pat. Appl. Publ., 134 pp., Cont.-in-part of U.S.
                         6,417,185.
```

CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20020156087	A1	20021024	US 2001-949035	20010906 <--
US 7045519	B2	20060516		
US 6417185	B1	20020709	US 1999-336038	19990618 <--
US 20030130289	A1	20030710	US 2002-309535	20021203 <--
US 7037918	B2	20060502		
US 20060089369	A1	20060427	US 2005-220400	20050906

PRIORITY APPLN. INFO.:

US 1998-89978P	P	19980619
US 1999-336038	A2	19990618
US 2000-230480P	P	20000906
US 1999-336098	A3	19990618
US 2001-949035	A3	20010906

OTHER SOURCE(S): MARPAT 137:325431
GI



I



II

AB Title compds. I [wherein W = (un)substituted C or N; X and Y = independently N, O, or (un)substituted C; A = (un)substituted (hetero)aryl; R1, R1a, R2, R2a, R3, R3a, R4, and R4a = independently H, OH, alkoxy, acyl, (hetero)aryl, or (un)substituted (cyclo)alkyl, amino(alkyl), etc. ; R5 and R7 = independently H, halo, alkoxy, guanidinyl, (bi)aryl, hetero(bi)aryl, heterocycloalkyl, arylsulfonamido, or (un)substituted (cyclo)alkyl, amino(alkoxy), or amidino; R6 = H, halo, carboxyl, NO2, (cyclo)amido, (cyclo)amidino, (cyclo)imido, CN, alkoxy, acyl(oxy), guanidinyl, (hetero)aryl, heterocyclo(alkyl), arylsulfonyl, arylsulfonamido, or (un)substituted alkyl, amino, etc.] were prepared as glycogen synthase kinase 3 (GSK3) inhibitors. For example, 2-chloro-5-nitropyridine was aminated by H2N(CH2)3NH2 and the product N-acylated by benzotriazolecarboxamidinium tosylate to give the alkylguanidine. The latter was cyclocondensed with resin-bound 4-(MeCO)C6H4CONHCH2C6H4Br-3 and Cs2CO3 to afford, after resin cleavage, the pyrimidinamine II. The most preferred compds. of the invention exhibited inhibitory activity against human GSK3β in a cell free

assay with IC50 values of < 1 μM. Thus, I and compns. containing I may be employed alone or in combination with other pharmacol. active agents in the treatment of disorders mediated by GSK3 activity, such as diabetes, Alzheimer's disease and other neurodegenerative disorders, obesity, atherosclerotic cardiovascular disease, essential hypertension, polycystic ovary syndrome, syndrome X, ischemia, traumatic brain injury, bipolar disorder, immunodeficiency, or cancer (no data).

REFERENCE COUNT: 306 THERE ARE 306 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d l9 ibib abs hitstr 2-
YOU HAVE REQUESTED DATA FROM 7 ANSWERS - CONTINUE? Y/(N):y

L9 ANSWER 2 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2002:185092 CAPLUS
DOCUMENT NUMBER: *136:247598*
TITLE: Preparation of aminopyrimidines and -pyridines as glycogen synthase kinase 3 inhibitors
INVENTOR(S): Nuss, John M.; Harrison, Stephen D.; Ring, David B.; Boyce, Rustum S.; Johnson, Kirk; Pfister, Keith B.; Ramurthy, Savithri; Seely, Lynn; Wagman, Allan S.; Desai, Manoj; Levine, Barry H.
PATENT ASSIGNEE(S): Chiron Corporation, USA
SOURCE: PCT Int. Appl., 268 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002020495	A2	20020314	WO 2001-US42081	20010906 <--
WO 2002020495	A3	20020620		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2001095026	A	20020322	AU 2001-95026	20010906 <--
EP 1317433	A2	20030611	EP 2001-975734	20010906 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004514656	T	20040520	JP 2002-525117	20010906
CN 1592743	A	20050309	CN 2001-818425	20010906
IN 2003KN00277	A	20050311	IN 2003-KN277	20030305
KR 816769	B1	20080326	KR 2003-703327	20030306
KR 2008013026	A	20080212	KR 2008-701887	20080124

PRIORITY APPLN. INFO.:	US 2000-230480P	P	20000906
	WO 2001-US42081	W	20010906
	KR 2003-703327	A3	20030306

OTHER SOURCE(S): MARPAT 136:247598
GI



I



II

AB Title compds. I [wherein W = (un)substituted C or N; X and Y = independently N, O, or (un)substituted C; A = (un)substituted (hetero)aryl; R1, R1a, R2, R2a, R3, R3a, R4, and R4a = independently H, OH, alkoxy, acyl, (hetero)aryl, or (un)substituted (cyclo)alkyl, amino(alkyl), etc. ; R5 and R7 = independently H, halo, alkoxy, guanidinyl, (bi)aryl, hetero(bi)aryl, heterocycloalkyl, arylsulfonamido, or (un)substituted (cyclo)alkyl, amino(alkoxy), or amidino; R6 = H, halo, carboxyl, NO2, (cyclo)amido, (cyclo)amidino, (cyclo)imido, CN, alkoxy, acyl(oxy), guanidinyl, (hetero)aryl, heterocyclo(alkyl), arylsulfonyl, arylsulfonamido, or (un)substituted alkyl, amino, etc.] were prepared as glycogen synthase kinase 3 (GSK3) inhibitors. For example, 2-chloro-5-nitropyridine was aminated by H2N(CH2)3NH2 and the product N-acylated by benzotriazolecarboxamidinium tosylate to give the alkylguanidine. The latter was cyclocondensed with resin-bound 4-(MeCO)C6H4CONHCH2C6H4Br-3 and Cs2CO3 to afford, after resin cleavage, the pyrimidinamine II. The most preferred compds. of the invention exhibited inhibitory activity against human GSK3β in a cell free assay with IC50 values of < 1 μM. Thus, I and compns. containing I may be employed alone or in combination with other pharmacol. active agents in the treatment of disorders mediated by GSK3 activity, such as diabetes, Alzheimer's disease and other neurodegenerative disorders, obesity, atherosclerotic cardiovascular disease, essential hypertension, polycystic ovary syndrome, syndrome X, ischemia, traumatic brain injury, bipolar disorder, immunodeficiency, or cancer (no data).

L9 ANSWER 3 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2001:763522 CAPLUS

DOCUMENT NUMBER: *135:283233*

TITLE: Pharmaceutical use of adenosine agonists for inducing bone marrow cell proliferation

INVENTOR(S): Fishman, Pnina; Cohn, Ilan

PATENT ASSIGNEE(S): Can-Fite Biopharma Ltd., Israel

SOURCE: U.S. Pat. Appl. Publ., 10 pp., Cont.-in-part of U.S. Ser. No. 700,744.
CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20010031742	A1	20011018	US 2001-782259	20010214 <--
US 6790839	B2	20040914		
WO 2000040251	A1	20000713	WO 2000-IL14	20000107 <--
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
US 6638914	B1	20031028	US 2001-700744	20010109 <--
US 20020037871	A1	20020328	US 2001-871963	20010604 <--

PRIORITY APPLN. INFO.:	IL 1999-127947	A	19990107
	WO 2000-IL14	P	20000107
	US 2001-700744	A2	20010109
	US 2001-782259	A2	20010214

OTHER SOURCE(S): MARPAT 135:283233

AB A method is provided for inducing proliferation of bone marrow cells in a subject, compromising administering an effective amount of an adenosine A1 receptor agonist. Also provided is a method for preventing reduction in level of leukocytes in a subject as a result of a treatment comprising administering to the individual an effective amount of an adenosine A1 receptor agonist. In addition, the invention provides a method of treatment of an individual comprising administering to the subject a therapeutic drug in combination with an adenosine A1 receptor agonist.

REFERENCE COUNT: 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 4 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1996:734085 CAPLUS
DOCUMENT NUMBER: *126:19178*
TITLE: Nucleotide inotropic agents
INVENTOR(S): Liang, Bruce T.
PATENT ASSIGNEE(S): University of Pennsylvania, USA
SOURCE: PCT Int. Appl., 56 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9629345	A1	19960926	WO 1996-US3911	19960322 <--
W: CA, JP, US				
RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
US 5712258	A	19980127	US 1995-409350	19950323 <--
US 6255292	B1	20010703	US 1997-875050	19970923 <--
US 20030186929	A1	20031002	US 2003-396200	20030325 <--
US 7348315	B2	20080325		

PRIORITY APPLN. INFO.:	US 1995-409350	A2	19950323
	WO 1996-US3911	W	19960322

	US 1997-875050	A2	19970923
	US 2000-641491	B1	20000818

OTHER SOURCE(S): MARPAT 126:19178
GI



I

AB Nucleotides I [R1, R2 = halo, -R6(R7)pR8; R3 = H, halo, -R6(R7)pR8; R4 = OH, SH, NH2; R5 = OH, acetamido; R6 = NH, S; R7 = C1-C10 alkylene; R8 = H, NH2, CN, cycloalkyl having 3 to about 10 carbon atoms, or aryl having 3 to about 20 carbon atoms; X, Y = N , CH; n, q, p = 0, 1; m = 1, 2] or their pharmaceutically acceptable salts modulate cardiac muscle contractility and possess vasodilator activity. Receptors that bind the compds. are also provided.

L9 ANSWER 5 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1995:315533 CAPLUS
DOCUMENT NUMBER: *122:106398*
TITLE: Preparation of deoxythionucleosides as virucides
INVENTOR(S): Koszalka, George Walter; Van Draanen, Nanine Agneta; Freeman, George Andrew; Short, Steven Andersen
PATENT ASSIGNEE(S): Wellcome Foundation Ltd., UK
SOURCE: PCT Int. Appl., 56 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9401443	A1	19940120	WO 1993-GB1388	19930701 <--
W: AU, BB, BG, BR, CA, CZ, FI, HU, JP, KP, KR, KZ, LK, MG, MN, MW, NO, NZ, PL, RO, RU, SD, SK, UA, US, VN				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9345085	A	19940131	AU 1993-45085	19930701 <--
CN 1087089	A	19940525	CN 1993-109525	19930701 <--
ZA 9304742	A	19950103	ZA 1993-4742	19930701 <--
EP 648218	A1	19950419	EP 1993-914865	19930701 <--

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE
JP 07508531 T 19950921 JP 1993-503083 19930701 <--
PRIORITY APPLN. INFO.: GB 1992-14171 A 19920702
GB 1992-23180 A 19921105
WO 1993-GB1388 A 19930701
OTHER SOURCE(S): CASREACT 122:106398; MARPAT 122:106398
GI



I

AB Title compds. [I; R1 = halo, NR2R3, SOnR4, SOmOR4a, OR5, alkyl, alkenyl, alkynyl; R2, R3 = H, alkyl, cycloalkyl, alkenyl, (substituted) Ph, phenylalkyl; R2R3N = 3-7 membered heterocyclyl; m, n = 0-4; R4, R4a, R5 = alkyl, cycloalkyl, cycloalkylalkyl, alkoxy, (substituted) Ph, phenylalkyl], were prepared as virucides (no data). Thus, 2-amino-6-methoxypurine was kept with α,β-2'-deoxy-4'-thiouridine and trans-N-deoxyribosylase in pH 6.0 citrate buffer at 50° to give I (R1 = OMe). Generic I formulations are given. Use of I against infection by herpes virus, retrovirus, hepatitis virus, coxsackie virus, and hepatitis C virus is claimed.

L9 ANSWER 6 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1991:247683 CAPLUS
DOCUMENT NUMBER: *114:247683*
TITLE: Preparation of N-heteroarylpurin-6-amines as analgesics and anticonvulsants
INVENTOR(S): Effland, Richard Charles; Klein, Joseph Thomas; Davis, Larry; Olson, Gordon Edward
PATENT ASSIGNEE(S): Hoechst-Roussel Pharmaceuticals, Inc., USA
SOURCE: Eur. Pat. Appl., 25 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 402752	A1	19901219	EP 1990-110676	19900606 <--
EP 402752	B1	19950913		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
US 5017578	A	19910521	US 1989-363837	19890609 <--

ES 2078267	T3	19951216	ES 1990-110676	19900606	<--
IL 94665	A	19940624	IL 1990-94665	19900607	<--
CA 2018563	A1	19901209	CA 1990-2018563	19900608	<--
CA 2018563	C	20000919			
NO 9002555	A	19901210	NO 1990-2555	19900608	<--
AU 9056919	A	19901213	AU 1990-56919	19900608	<--
AU 636351	B2	19930429			
CN 1047866	A	19901219	CN 1990-104194	19900608	<--
CN 1029968	B	19951011			
HU 54156	A2	19910128	HU 1990-3768	19900608	<--
HU 207320	B	19930329			
JP 03024080	A	19910201	JP 1990-148884	19900608	<--
JP 06102663	B	19941214			
ZA 9004443	A	19910327	ZA 1990-4443	19900608	<--
KR 199524	B1	19990615	KR 1990-8444	19900609	<--
US 5155098	A	19921013	US 1991-696472	19910506	<--
KR 210179	B1	19990715	KR 1998-49161	19981117	<--

PRIORITY APPLN. INFO.: US 1989-363837 A 19890609
KR 1990-8444 A 19900609

OTHER SOURCE(S): CASREACT 114:247683; MARPAT 114:247683

GI



I II

AB The title compds. [I; R1 = H, alkyl, aralkyl; R2-R5 = H, alkyl, or R2R3 = arylene; R4R5 = arylene; R6 = H, alkyl, aryl, aralkyl, (substituted) 1H-pyrrol-1-yl, (substituted) ribofuranosyl] and their pharmaceutically acceptable salts were prepared by, e.g., reaction of QR6 [Q = 6-halo-9-purinyl] with pyrroleamine II. 6-Chloropurine was heated with II (R1 = R2 = R4 = R5 = H, R3 = Me) (preparation given) in Me2CHOH containing ether-HCl at 80° for 4 h to give 28% I [R1 = R2 = R4 = R5 = R6 = H, R3 = Me), which at 20.0 mg/kg s.c. inhibited 37% 2-phenyl-1,4-benzoquinone-induced writhing in mice.

L9 ANSWER 7 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1991:143930 CAPLUS
DOCUMENT NUMBER: *114:143930*
TITLE: Preparation of 5'N, 6-disubstituted adenosines from inosines
INVENTOR(S): Bridges, Alexander J.
PATENT ASSIGNEE(S): Warner-Lambert Co., USA
SOURCE: U.S., 7 pp. Cont. of U.S. Ser. No. 34,125, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4962194	A	19901009	US 1988-260202	19881019 <--
PRIORITY APPLN. INFO.:			US 1987-34125 B1	19870402

OTHER SOURCE(S): CASREACT 114:143930; MARPAT 114:143930

GI



I II

AB The title compds. [I; R2, R3 = H, alkyl, alkanoyl, Bz; or R2R3 = alkylidene; Z = RS(O)q, (un)substituted NH2; R = alkyl, (hetero)aryl, aralkyl; q = 0, 2; Q = H, halo, cyano, N3, NH2, alkoxy, acyloxy, thioalkyl, H2NNH, HONH, phosphino, dialkyl or diarylcuprato] are prepared by (1) bromination of inosine derivs. (II; R2, R3 = as defined above, excluding R2 = R3 = H) with Ar3PBr2 or (ArO)3PBr2 (Ar = aryl) followed by reaction with RSH (R = as defined above) to give I (Z = RS, Q = Br), (2) oxidation of the latter to I [Z = RS(O)q Q = Br], (3) amination of the latter with amines to give I [Z = (un)substituted NH2, Q = Br], and (4) treatment of the latter with a nucleophile. Some I are useful as neuroleptics, analgesics, cardiotonics, antihypertensives, antilipolytics, antihyperlipemics, antiinflammatory agents, antithrombotic or antiembolic agents (no data). Thus, bromination of 2',3'-isopropylideneinosine with Br/Ph3P in pyridine followed by reaction with PhSH gave I (Z = PhS, Q = Br, R1R3 = CMe2) which was oxidized with m-ClC6H4C(O)OOH in CHCl3 in the presence of NaHCO3 to I (Z = PhSO2; R, R2, R3 = as defined above). Amination of the latter with cyclopentylamine in the presence of Et3N in CHCl3 and thiolation of the product I (Z = cyclopentylamino; Q, R2, R3 = as defined above) with NaSMe in Me2SO followed by hydrolysis gave I (Z = cyclopentylamino, Q = MeS, R2 = R3 = H).

L9 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1990:423943 CAPLUS

DOCUMENT NUMBER: *113:23943*

TITLE: 6-Mercaptopurine derivatives, their preparation and their use against retrovirus infections

INVENTOR(S): Klosa, Josef; Kroeger, Hans Prof; Meichsner, Christoph; Winkler, Irvin; Helsberg, Matthias; Schrinner, Elmar

PATENT ASSIGNEE(S): Hoechst A.-G., Germany

SOURCE: Eur. Pat. Appl., 15 pp.

CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: German
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 350742	A1	19900117	EP 1989-112061	19890701 <--
R: AT, BE, CH, DE, ES, FR, GB, GR, IT, LI, LU, NL, SE				
DE 3823345	A1	19900125	DE 1988-3823345	19880709 <--
DK 8903383	A	19900110	DK 1989-3383	19890707 <--
AU 8937933	A	19900111	AU 1989-37933	19890707 <--
JP 02067283	A	19900307	JP 1989-174317	19890707 <--
ZA 8905176	A	19900328	ZA 1989-5176	19890707 <--

PRIORITY APPLN. INFO.: DE 1988-3823345 A 19880709
OTHER SOURCE(S): CASREACT 113:23943; MARPAT 113:23943
GI



I

AB The title compds. [I; X = C1-6 (unsatd.) (substituted) alkyl, C4-6 cycloalkyl, O- or NH-containing heterocycyl], were prepared Thus, 6-mercaptopurine and then H2C:CHCH2Br were added to KOH in H2O/EtOH to give I (X = CH2CH:CH2) (II). II at 1.0 mg/mL in drinking water reduced the increase in spleen weight of mice infected with Friend leukemia virus from 7.8 (untreated controls) to 1.51%.

=> logoff hold

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	36.04	291.27

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-6.40	-6.40

SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 10:03:23 ON 15 APR 2008